Cite
Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer
MLA
Togashi, Yosuke, et al. “Differences in Adverse Events between 250mg Daily Gefitinib and 150mg Daily Erlotinib in Japanese Patients with Non-Small Cell Lung Cancer.” Lung Cancer (01695002), vol. 74, no. 1, Oct. 2011, pp. 98–102. EBSCOhost, https://doi.org/10.1016/j.lungcan.2011.01.022.
APA
Togashi, Y., Masago, K., Fujita, S., Hatachi, Y., Fukuhara, A., Nagai, H., Sakamori, Y., Kim, Y. H., Mio, T., & Mishima, M. (2011). Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer (01695002), 74(1), 98–102. https://doi.org/10.1016/j.lungcan.2011.01.022
Chicago
Togashi, Yosuke, Katsuhiro Masago, Shiro Fujita, Yukimasa Hatachi, Akiko Fukuhara, Hiroki Nagai, Yuichi Sakamori, Young Hak Kim, Tadashi Mio, and Michiaki Mishima. 2011. “Differences in Adverse Events between 250mg Daily Gefitinib and 150mg Daily Erlotinib in Japanese Patients with Non-Small Cell Lung Cancer.” Lung Cancer (01695002) 74 (1): 98–102. doi:10.1016/j.lungcan.2011.01.022.